138 related articles for article (PubMed ID: 7222858)
1. [Monitoring of heparin therapy with activated recalcification time].
Lutze G; Schlote A; Urbahn H
Z Gesamte Inn Med; 1981 Feb; 36(4):102-6. PubMed ID: 7222858
[TBL] [Abstract][Full Text] [Related]
2. [Laboratory controls of heparin therapy with thrombin time, partial thromboplastin time and activated recalcification time].
Lutze G; Presser HJ; Urbahn H
Z Gesamte Inn Med; 1989 Apr; 44(8):235-40. PubMed ID: 2662657
[TBL] [Abstract][Full Text] [Related]
3. Clotting, activated partial thromboplastin and coagulation times in monitoring heparin therapy.
Kurec AS; Morris MW; Davey FR
Ann Clin Lab Sci; 1979; 9(6):494-500. PubMed ID: 518012
[TBL] [Abstract][Full Text] [Related]
4. [Monitoring heparin therapy by thrombin time and activated partial thromboplastin time--a comparison].
Lang M; Fey MF; Furlan M; Beck EA
Schweiz Med Wochenschr; 1986 Nov; 116(48):1681-4. PubMed ID: 3798064
[TBL] [Abstract][Full Text] [Related]
5. [Is the activated partial thromboplastin time suitable for monitoring of thrombosis therapy with high-dose standard heparin?].
Hürzeler C; von Felten A
Schweiz Med Wochenschr; 1994 Apr; 124(17):712-9. PubMed ID: 8202668
[TBL] [Abstract][Full Text] [Related]
6. [Monitoring of heparin therapy using thrombin time and activated partial thromboplastin time--a comparison].
Osterwalder J
Schweiz Med Wochenschr; 1987 Apr; 117(14):539-40. PubMed ID: 3576165
[No Abstract] [Full Text] [Related]
7. [Modification of the global coagulation tests for the dog. Significance for the monitoring of heparin therapy].
Mischke R; Nolte I
Tierarztl Prax; 1991 Oct; 19(5):561-6. PubMed ID: 1759273
[TBL] [Abstract][Full Text] [Related]
8. [Clinical value of a new method of therapeutic control of heparin].
Pizzuto J; Garcia S; de la Paz Reyna M; Morales MR; Avilés A; Zavala B; Ponce L; Gaos C
Arch Inst Cardiol Mex; 1978; 48(2):373-86. PubMed ID: 666447
[TBL] [Abstract][Full Text] [Related]
9. The monitoring of heparin administration by screening tests in experimental dogs.
Mischke R; Jacobs C
Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a new potent heparin. 1 communication: Determinations of anticoagulant activity of a high potency heparin preparation in vivo using dog as an experimental animal and in vitro using dog and human plasma.
Bhargava AS; Heinick J; Schöbel C; Günzel P
Arzneimittelforschung; 1980; 30(6):993-6. PubMed ID: 7191280
[TBL] [Abstract][Full Text] [Related]
11. Thrombin time dilution test: a simple method for the control of heparin therapy.
Pizzuto J; García-Méndez S; de-la-Paz Reyna M; Morales MR; Avilés A; Zavala B; Gaos C
Thromb Haemost; 1979 Dec; 42(4):1276-85. PubMed ID: 542933
[No Abstract] [Full Text] [Related]
12. Problems by using whole blood in heparin measurements.
Talstad I
Thromb Haemost; 1982 Apr; 47(2):177-81. PubMed ID: 7101239
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of point-of-care activated partial thromboplastin time testing by comparison to laboratory-based assay for control of intravenous heparin.
Douglas AD; Jefferis J; Sharma R; Parker R; Handa A; Chantler J
Angiology; 2009; 60(3):358-61. PubMed ID: 19398428
[TBL] [Abstract][Full Text] [Related]
14. [Laboratory control of anticoagulant treatments (author's transl)].
Samama M; Conard J; Horellou MH
J Mal Vasc; 1981; 6(4):257-61. PubMed ID: 7320641
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III.
Bounameaux H; Marbet GA; Lämmle B; Eichlisberger R; Duckert F
Am J Clin Pathol; 1980 Jul; 74(1):68-73. PubMed ID: 7395817
[TBL] [Abstract][Full Text] [Related]
16. [Activated thromboplastin time, plasma heparin and plasma fibrinogen using the Fibrintimer 10].
Khayat MC; Laforet F; Khayat A; Derlon A; Lequerrec A; Thomas M
Ann Biol Clin (Paris); 1988; 46(8):696-700. PubMed ID: 3218791
[TBL] [Abstract][Full Text] [Related]
17. [Comparative multicenter study of a rabbit high-sensitivity thromboplastin and a recombinant thromboplastin with synthetic phospholipids].
Martínez-Brotóns F; Borrell M; Fontcuberta J; Batlle J; López F; Páramo JA; Ribera C; Rocha E; Vicente V; Zuazu I
Sangre (Barc); 1994 Aug; 39(4):245-51. PubMed ID: 7985052
[TBL] [Abstract][Full Text] [Related]
18. The effect of aprotinin on the response of the activated partial thromboplastin time (APTT) to heparin.
Francis JL; Howard C
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):35-40. PubMed ID: 7681330
[TBL] [Abstract][Full Text] [Related]
19. [The kaolin-activated recalcification test in the screening of coagulation disorders and in the control of anticoagulant therapy].
Barberi G; Fiocca S
Quad Sclavo Diagn; 1977 Jun; 13(2):167-75. PubMed ID: 594303
[TBL] [Abstract][Full Text] [Related]
20. [Monitoring of heparin therapy].
Camici M; Evangelisti L
Minerva Med; 1993 Oct; 84(10):507-9. PubMed ID: 8247304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
